These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15807367)

  • 21. Patents. NIH declines to march in on pricing AIDS drug.
    Malakoff D
    Science; 2004 Aug; 305(5686):926. PubMed ID: 15310867
    [No Abstract]   [Full Text] [Related]  

  • 22. Razing the tollbooths. A call for restricting patents on basic biomedical research.
    Stix G
    Sci Am; 2003 Apr; 288(4):37. PubMed ID: 12661312
    [No Abstract]   [Full Text] [Related]  

  • 23. Controversy over ritonavir price increase.
    AIDS Clin Care; 2004 Feb; 16(2):15. PubMed ID: 15032179
    [No Abstract]   [Full Text] [Related]  

  • 24. Patents, profits, and the American people--the Bayh-Dole Act of 1980.
    Markel H
    N Engl J Med; 2013 Aug; 369(9):794-6. PubMed ID: 23984726
    [No Abstract]   [Full Text] [Related]  

  • 25. Bayh-Dole: if we knew then what we know now.
    Boettiger S; Bennett AB
    Nat Biotechnol; 2006 Mar; 24(3):320-3. PubMed ID: 16525405
    [No Abstract]   [Full Text] [Related]  

  • 26. Columbia University's Axel patents: technology transfer and implications for the Bayh-Dole Act.
    Colaianni A; Cook-Deegan R
    Milbank Q; 2009 Sep; 87(3):683-715. PubMed ID: 19751286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intellectual property. University licensing and the Bayh-Dole Act.
    Thursby JG; Thursby MC
    Science; 2003 Aug; 301(5636):1052. PubMed ID: 12933996
    [No Abstract]   [Full Text] [Related]  

  • 28. Is Bayh-Dole good for developing countries? Lessons from the US experience.
    So AD; Sampat BN; Rai AK; Cook-Deegan R; Reichman JH; Weissman R; Kapczynski A
    PLoS Biol; 2008 Oct; 6(10):e262. PubMed ID: 18959484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug pricing. AHF presses for indemnification over Norvir price increase.
    AIDS Policy Law; 2004 Feb; 19(4):2. PubMed ID: 15045980
    [No Abstract]   [Full Text] [Related]  

  • 30. NIH funding for patents that contribute to market exclusivity of drugs approved 2010-2019 and the public interest protections of Bayh-Dole.
    Ledley FD; Cleary EG
    PLoS One; 2023; 18(7):e0288447. PubMed ID: 37494368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Open letter from ATAC to Abbott's CEO, Miles White.
    Dee L; Sharp M
    GMHC Treat Issues; 2003 Dec; 17(12):5. PubMed ID: 15011642
    [No Abstract]   [Full Text] [Related]  

  • 32. RTV patent under fire.
    Roehr B
    IAPAC Mon; 2004 Jun; 10(6):189-90. PubMed ID: 15484369
    [No Abstract]   [Full Text] [Related]  

  • 33. Research and the Bayh-Dole Act.
    Reczek PR
    Science; 2004 Jan; 303(5654):40. PubMed ID: 14704412
    [No Abstract]   [Full Text] [Related]  

  • 34. Technology transfer at US universities: seeking public benefit from the results of basic research.
    Goodwin CD
    Technol Health Care; 1996 Sep; 4(3):323-30. PubMed ID: 8931243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intellectual property issues in a clinical trial: a corporate perspective.
    Fersko RS; Connolly MJ
    Qual Assur; 1992 Jun; 1(3):237-48. PubMed ID: 1344679
    [No Abstract]   [Full Text] [Related]  

  • 36. Norvir hangover.
    Clifton CE
    Posit Aware; 2004; 15(2):7-9. PubMed ID: 15106524
    [No Abstract]   [Full Text] [Related]  

  • 37. Patents, pills and politics: the Australia-United States Free Trade Agreement and the Pharmaceutical Benefits Scheme.
    Harvey K
    Aust Health Rev; 2004 Nov; 28(2):218-26. PubMed ID: 15527402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Cipro patent and bioterrorism.
    Kaye KS; Kaye D
    Am J Bioeth; 2002; 2(3):41-2. PubMed ID: 12230854
    [No Abstract]   [Full Text] [Related]  

  • 39. Government-industry collaboration. NIH panel rejects pricing clause.
    Anderson C
    Science; 1994 Jul; 265(5172):598. PubMed ID: 8036506
    [No Abstract]   [Full Text] [Related]  

  • 40. Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro.
    Resnik DB; DeVille KA
    Am J Bioeth; 2002; 2(3):29-39. PubMed ID: 12230852
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.